Related Experiment Video
Updated: Jun 23, 2026

Mass Spectrometry Analysis to Identify Ubiquitylation of EYFP-tagged CENP-A EYFP-CENP-A
Published on: June 10, 2020
Tetraploidy-linked sensitization to CENP-E inhibition in human cells
Koya Yoshizawa1, Akira Matsura1, Masaya Shimada1
1Graduate School of Life Science, Hokkaido University, Sapporo, Japan.
Abstract:
Tetraploidy is a hallmark of cancer cells, and tetraploidy-selective cell growth suppression is a potential strategy for targeted cancer therapy. However, how tetraploid cells differ from normal diploids in their sensitivity to anti-proliferative treatments remains largely unknown. In this study, we found that tetraploid cells are significantly more susceptible to inhibitors of a mitotic kinesin (CENP-E) than are diploids. Treatment with a CENP-E inhibitor preferentially diminished the tetraploid cell population in a diploid-tetraploid co-culture at optimum conditions. Live imaging revealed that a tetraploidy-linked increase in unsolvable chromosome misalignment caused substantially longer mitotic delay in tetraploids than in diploids upon moderate CENP-E inhibition. This time gap of mitotic arrest resulted in cohesion fatigue and subsequent cell death, specifically in tetraploids, leading to tetraploidy-selective cell growth suppression. In contrast, the microtubule-stabilizing compound paclitaxel caused tetraploidy-selective suppression through the aggravation of spindle multipolarization. We also found that treatment with a CENP-E inhibitor had superior generality to paclitaxel in its tetraploidy selectivity across a broader spectrum of cell lines. Our results highlight the unique properties of CENP-E inhibitors in tetraploidy-selective suppression and their potential use in the development of tetraploidy-targeting interventions in cancer.
Insights
Tetraploid cancer cells are more vulnerable to CENP-E inhibitors, which cause mitotic delay and cell death. This discovery offers a new strategy for targeted cancer therapy by selectively suppressing tetraploid cells.
Area of Science:
- Cell Biology
- Cancer Biology
- Pharmacology
Background:
- Tetraploidy is common in cancer cells.
- Targeting tetraploid cells is a potential cancer therapy strategy.
- Differences in anti-proliferative treatment sensitivity between diploid and tetraploid cells are not well understood.
Purpose of the Study:
- To investigate the differential sensitivity of tetraploid versus diploid cells to anti-proliferative treatments.
- To identify mechanisms underlying tetraploidy-selective cell growth suppression.
Main Methods:
- Co-culture of diploid and tetraploid cells.
- Treatment with a CENP-E inhibitor and paclitaxel.
- Live imaging to observe mitotic progression and chromosome alignment.
- Assessment of cell viability and population dynamics.
Main Results:
- Tetraploid cells showed significantly higher susceptibility to CENP-E inhibitors compared to diploid cells.
- CENP-E inhibition led to prolonged mitotic delay in tetraploid cells due to chromosome misalignment, causing cell death.
- Paclitaxel induced tetraploidy-selective suppression by worsening spindle multipolarization.
- CENP-E inhibitors demonstrated broader tetraploidy selectivity across various cell lines than paclitaxel.
Conclusions:
- Tetraploid cells exhibit unique vulnerabilities to specific anti-proliferative agents.
- CENP-E inhibitors offer a promising approach for tetraploidy-selective cancer therapy.
- Understanding these differential sensitivities can guide the development of novel cancer interventions.
More Related Videos
09:41Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry
Published on: December 28, 2021
11:49Author Spotlight: Establishing CENP-E Knockout HeLa Cells – A Novel Approach to Study Kinesin-7 CENP-E Biology and its Inhibitors
Published on: June 23, 2023
Related Concept Videos
Karyotyping
Centrosome Duplication
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
Nondisjunction